Kelun-Biotech's Sac-TMT Combination Therapy Enters Priority Review for First-Line NSCLC in China
Event summary
- Kelun-Biotech's supplemental New Drug Application (sNDA) for sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab as first-line treatment for PD-L1-positive NSCLC accepted for review by China's NMPA on May 8, 2026.
- The application is based on positive Phase III OptiTROP-Lung05 study results showing statistically significant improvement in progression-free survival (PFS) and a positive trend in overall survival (OS).
- This is the fifth indication application for sac-TMT accepted by NMPA, with the review process entering priority status, potentially expediting approval.
- Sac-TMT has previously received four marketing approvals in China and six Breakthrough Therapy Designations (BTDs) from NMPA.
The big picture
This development represents a significant step in the evolution of first-line NSCLC treatment in China, combining targeted therapy with immunotherapy. The acceptance of this application underscores the growing importance of antibody-drug conjugates (ADCs) in oncology, particularly in addressing unmet needs in lung cancer treatment. With MSD's global reach and Kelun-Biotech's domestic expertise, this collaboration could reshape the competitive landscape for NSCLC therapies both in China and potentially worldwide.
What we're watching
- Regulatory Approval Timeline
- The pace at which NMPA completes its priority review will determine when sac-TMT combination therapy becomes available for first-line NSCLC treatment in China.
- Commercialization Strategy
- How Kelun-Biotech and MSD will position this combination therapy against existing first-line NSCLC treatments in the Chinese market.
- Global Expansion Potential
- Whether positive results from the OptiTROP-Lung05 study will accelerate global Phase III trials led by MSD for other cancer indications.
Related topics